MX2019015502A - L-asparaginasa modificada. - Google Patents

L-asparaginasa modificada.

Info

Publication number
MX2019015502A
MX2019015502A MX2019015502A MX2019015502A MX2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A MX 2019015502 A MX2019015502 A MX 2019015502A
Authority
MX
Mexico
Prior art keywords
modified protein
asparaginase
poly
modified
amino acid
Prior art date
Application number
MX2019015502A
Other languages
English (en)
Spanish (es)
Inventor
Lars Friedrich
Anne O''DONNELL
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17177237.9A external-priority patent/EP3418383A1/en
Priority claimed from US15/671,086 external-priority patent/US10174302B1/en
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2019015502A publication Critical patent/MX2019015502A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82Asparaginase (3.5.1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001Asparaginase (3.5.1.1)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2019015502A 2017-06-21 2018-06-21 L-asparaginasa modificada. MX2019015502A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762523061P 2017-06-21 2017-06-21
EP17177237.9A EP3418383A1 (en) 2017-06-21 2017-06-21 Modified l-asparaginase
US15/671,086 US10174302B1 (en) 2017-06-21 2017-08-07 Modified L-asparaginase
PCT/EP2018/066647 WO2018234492A1 (en) 2017-06-21 2018-06-21 L-ASPARAGINASE MODIFIED

Publications (1)

Publication Number Publication Date
MX2019015502A true MX2019015502A (es) 2020-07-28

Family

ID=64737515

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019015502A MX2019015502A (es) 2017-06-21 2018-06-21 L-asparaginasa modificada.
MX2024015050A MX2024015050A (es) 2017-06-21 2019-12-18 L-asparaginasa modificada

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024015050A MX2024015050A (es) 2017-06-21 2019-12-18 L-asparaginasa modificada

Country Status (15)

Country Link
EP (2) EP4180525A1 (enExample)
JP (2) JP7808424B2 (enExample)
KR (1) KR102727396B1 (enExample)
CN (1) CN111315878B (enExample)
AU (1) AU2018287145B2 (enExample)
BR (1) BR112019027479A2 (enExample)
CA (1) CA3068100A1 (enExample)
DK (1) DK3642340T3 (enExample)
ES (1) ES2979314T3 (enExample)
FI (1) FI3642340T3 (enExample)
IL (1) IL271504B2 (enExample)
MX (2) MX2019015502A (enExample)
SA (2) SA519410870B1 (enExample)
SG (1) SG11201912625QA (enExample)
WO (1) WO2018234492A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017109087A1 (en) 2015-12-22 2017-06-29 Xl-Protein Gmbh Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
SG11201912625QA (en) * 2017-06-21 2020-01-30 Jazz Pharmaceuticals Ireland Ltd Modified l-asparaginase
US20200354706A1 (en) * 2017-11-22 2020-11-12 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CA3156066A1 (en) * 2019-10-25 2021-04-29 Mi Rim Choi Recombinant l-asparaginase
AU2021410080A1 (en) * 2020-12-23 2023-06-22 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20260007728A1 (en) 2022-07-14 2026-01-08 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8519753D0 (en) * 1985-08-06 1985-09-11 Health Lab Service Board Production of 1-asparaginase
GB9017002D0 (en) * 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP2851424B1 (en) * 2007-03-09 2016-09-21 Novozymes A/S Thermostable asparaginases
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
US9221882B2 (en) * 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Xten共役組成物およびそれを製造する方法
SG11201912625QA (en) * 2017-06-21 2020-01-30 Jazz Pharmaceuticals Ireland Ltd Modified l-asparaginase

Also Published As

Publication number Publication date
FI3642340T3 (fi) 2024-06-18
JP7770352B2 (ja) 2025-11-14
KR102727396B1 (ko) 2024-11-08
IL271504A (en) 2020-02-27
EP4180525A1 (en) 2023-05-17
CN111315878B (zh) 2024-04-26
KR20200030065A (ko) 2020-03-19
IL271504B1 (en) 2024-01-01
SA519410870B1 (ar) 2023-03-06
CA3068100A1 (en) 2018-12-27
AU2018287145B2 (en) 2024-04-18
SA522433360B1 (ar) 2024-06-23
DK3642340T3 (da) 2024-06-03
JP7808424B2 (ja) 2026-01-29
AU2018287145A1 (en) 2020-02-06
IL271504B2 (en) 2024-05-01
ES2979314T3 (es) 2024-09-25
EP3642340B1 (en) 2024-03-20
RU2020101972A3 (enExample) 2021-11-09
EP3642340A1 (en) 2020-04-29
MX2024015050A (es) 2025-01-09
CN111315878A (zh) 2020-06-19
RU2020101972A (ru) 2021-07-21
JP2023081915A (ja) 2023-06-13
JP2020528743A (ja) 2020-10-01
WO2018234492A1 (en) 2018-12-27
BR112019027479A2 (pt) 2020-09-15
SG11201912625QA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
EA201101553A1 (ru) Полипептид, деградирующий углеводы, и его применения
MX2020012332A (es) Casetes de expresion de alfa-glucosidasa de acido optimizado con codon y metodos de uso del mismo.
MX2023001394A (es) Genes del factor viii optimizados.
EP4467650A3 (en) Scaffold proteins
WO2014202616A3 (en) Rasamsonia gene and use thereof
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
MX2020005458A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
MX2012015142A (es) Polipeptidos que tiene actividad beta-glucosidasa y usos del mismo.
IN2012DN02981A (enExample)
GB201201178D0 (en) Novel enzymes
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
PH12015500461A1 (en) Novel il-17a binding molecules and medical uses thereof
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
WO2016130628A8 (en) Griffithsin mutants
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
MY167485A (en) Recombinant human interferon-like proteins
MY195726A (en) Steviol Glycoside Transport
PH12018500468A1 (en) Fusion protein
AR071534A1 (es) Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa
RU2013111675A (ru) Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc
MY187334A (en) Xylanase
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение